PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Mesalazine - Inflammatory bowel disease

PAD Profile : Mesalazine - Inflammatory bowel disease Important

Keywords :
Ulcerative colitis, UC, IBD, aminosalicylates, chronic bowel disorders
Brand Names Include :
Octasa, Salofalk Granules, Pentasa, Mezavant, Zintasa
Important Information :
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.

Traffic Light Status

Status 1 of 6.

Status :
Green (see narrative)
Important Preferred
Formulations :
  • Gastro-resistant tablets
Important Information :
Prescribe by brand.: Octasa or Salofalk gastro resistant tablets (or Salofalk granules) are 1st line for new patients Asacol tablets are non-formulary
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 6.

Status :
Green (see narrative)
Important
Formulations :
  • Suppositories
Important Information :
Prescribe by brand: Octasa, Salofalk, Pentasa
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 3 of 6.

Status :
Green (see narrative)
Important
Formulations :
  • Modified release tablets
Important Information :
Mezevant XL - Reserve for patients with a high pill burden.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 4 of 6.

Status :
Green (see narrative)
Important Preferred
Formulations :
  • Granules (slow release)
  • Modified release tablets
Important Information :
Prescribe by brand: Salofalk granules are a 1st-line option for new patients. Pentasa modified-release tablets and granules for patients who require upper GI release.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 5 of 6.

Status :
Green (see narrative)
Important
Formulations :
  • Enema
  • Foam enema
Important Information :
Prescribe by brand: Pentasa / Salofalk enema
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 6 of 6.

Status :
Non Formulary
Important
Formulations :
  • Gastro-resistant tablets
Important Information :
Asacol 400mg gastro resitsant tablets have been discontinued. The 800mg tablets are non-formulary.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
07 July 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Mesalazine therapy is included within the locally agreed pathway for Ulcerative Colitis (see pathway document below).


Mesalazine therapy should be prescribed by BRAND. The following brands have been considered by the APC: 

  • Salofalk® gastro-resistant tablets and granules - 1st line for new patients
  • Octasa® MR gastro-resistant tablets - 1st line for new patients
  • Pentasa® modified-release tablets and granules -  1st line for patients who require upper GI release
  • Mezavant® XL tablets -  Alternative choice for patients with high pill burden

Choice is dependent on required site of release and factors that may aid adherence to therapy.  Prescribe by brand to ensure continuation of those chosen properties

Asacol® MR gastro-resistant tablets are non-formulary and least cost-effective option - can continue in existing patients with good disease control (see separate page https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6208).  Octasa® MR has the same release properties as Asacol® MR

Associated BNF Codes

01. Gastro-Intestinal System
01.05.01. Aminosalicylates
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More